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Cell cycle arrest 
A B S T R A C T   
Background: Obesity and type 2 diabetes mellitus, which are widespread throughout the world, require thera-
peutic interventions targeted to solve clinical problems (insulin resistance, hyperglycaemia, dyslipidaemia and 
steatosis). Several natural compounds are now part of the therapeutic repertoire developed to better manage 
these pathological conditions. Cladosporols, secondary metabolites from the fungus Cladosporium tenuissimum, 
have been characterised for their ability to control cell proliferation in human colon cancer cell lines through 
peroxisome proliferator-activated receptor gamma (PPARγ)-mediated modulation of gene expression. Here, we 
report data concerning the ability of cladosporols to regulate the differentiation of murine 3T3-L1 preadipocytes. 
Methods: Cell counting and MTT assay were used for analysing cell proliferation. RT-PCR and Western blotting 
assays were performed to evaluate differentiation marker expression. Cell migration was analysed by wound- 
healing assay. 
Results: We showed that cladosporol A and B inhibited the storage of lipids in 3T3-L1 mature adipocytes, while 
their administration did not affect the proliferative ability of preadipocytes. Moreover, both cladosporols 
downregulated mRNA and protein levels of early (C/EBPα and PPARγ) and late (aP2, LPL, FASN, GLUT-4, 
adiponectin and leptin) differentiation markers of adipogenesis. Finally, we found that proliferation and 
migration of HT-29 colorectal cancer cells were inhibited by conditioned medium from cladosporol-treated 3T3- 
L1 cells compared with the preadipocyte conditioned medium. 
Conclusions: To our knowledge, this is the first report describing that cladosporols inhibit in vitro adipogenesis 
and through this inhibition may interfere with HT-29 cancer cell growth and migration. 
General significance: Cladosporols are promising tools to inhibit concomitantly adipogenesis and control colon 
cancer initiation and progression.   
1. Introduction 
Obesity is a risk factor for several diseases such as type 2 diabetes, 
metabolic syndrome, hypertension, hyperlipidaemia, atherosclerosis 
and cancer. Hyperplasia (an increase in adipocyte numbers) and hy-
pertrophy (an increase in adipocyte mass) both lead to obesity [1]. 
Genetics, metabolism, nutritional status, exercise and, in general, habits 
of life may differentially contribute to the development of obesity. 
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Endogenous lipogenesis and storage of external lipids in mature adipo-
cytes are relevant steps in adipogenesis [2]. For these reasons, reduction 
of adipose depots through inhibition of lipogenesis and the simultaneous 
promotion of lipolysis have been identified as crucial therapeutic in-
terventions for obesity treatment [3,4]. Investigations about molecules 
that interfere with preadipocyte differentiation to mature adipocytes 
have received considerable attention from clinical and molecular re-
searchers. Indeed, an increasing number of papers have demonstrated 
that several natural compounds may inhibit adipogenesis and lipogen-
esis, promote lipolysis and also induce apoptosis of adipocytes [5]. 
Peroxisome proliferator-activated receptor gamma (PPARγ or 
NR1C3), together with its isoforms PPARα (NR1C1) and PPARβ/δ 
(NP1X2), are type II nuclear receptors that are usually inactive in the 
nucleus until they bind to a ligand [6,7]. Ligand binding causes a 
conformational change in the receptor structure that, in turn, provokes 
the displacement of corepressors and the recruitment of coactivators. 
Ligand-activated PPARγ forms a heterodimer with retinoid X receptor 
(RXR); this heterodimer binds to the PPAR response element (PPRE) and 
stimulates the transcription of several gene targets that, consequently, 
modulate the metabolism of carbohydrates and lipids, cell proliferation 
and differentiation, angiogenesis and inflammation [8]. In humans, four 
distictive messenger RNAs (mRNAs) are transcribed from the unique 
PPARγ gene; they result from different promoter usage and alternative 
splicing. PPARγ1, PPARγ3 and PPARγ4 mRNAs generate the same pro-
tein product, namely PPARγ1 (477 amino acids), while PPARγ2 mRNA 
produces the PPARγ2 isoform, which contains 30 additional amino acids 
at the N-terminus (507 amino acids) [9]. The PPARγ1 isoform is 
expressed in many tissues including white and brown adipose tissue 
(WAT and BAT, respectively), the heart, the kidneys, immune cells such 
as macrophages, skeletal muscle, the pancreas and the colon. 
Conversely, the expression of PPARγ2 is restricted to adipose tissue but 
may be induced in other tissues by a high-fat diet [10,11]. PPARγ is 
considered a master regulator gene of adipocyte differentiation and 
plays a key role in adipogenesis. Analysis of the PPARγ-null mouse, 
which lacks adipose tissue, definitively established this crucial function 
[12]. PPARγ has also been found in an adipocyte progenitor population 
within the WAT perivascular niche; this finding suggests that it may play 
a pivotal role in adipocyte self-renewal [13]. Finally, PPARγ is necessary 
to maintain the mature adipocyte phenotype because selective PPARγ 
ablation in this cell type only allows survival for a few days, followed by 
death [14]. 
Besides its role in adipocyte differentiation and lipid metabolism, 
PPARγ controls the gene networks involved in glucose homeostasis. 
Moreover, it modulates the synthesis and secretion of various adipokines 
(adiponectin, resistin, leptin and tumour necrosis factor [TNF-α]), which 
control insulin sensitivity [15]. PPARγ target genes may exert their 
functions in different tissues, and thus they can positively influence in-
sulin sensitivity through a wide range of mechanisms. For example, TNF- 
α acts on inflammation, adiponectin on glucose utilisation and insulin on 
nutrient uptake. Administration of PPARγ ligands may be considered a 
powerful therapeutic intervention capable of targeting multiple over-
lapping pathways and directed to solve different dysfunctions in a 
multifactorial disease such as diabetes and obesity. Natural and syn-
thetic ligands have been found to bind PPARγ; among them are the 
thiazolinediones (TZDs), which at one time were the most used sensi-
tisers of insulin signaling in the treatment of type 2 diabetes mellitus 
[16,17]. Unfortunately, their use was associated with side effects and 
adverse events (hepatic injury, cardiovascular events, weight gain, fluid 
retention, bone fractures, oedema and cancer); hence, they have been 
removed from the market or their use is restricted [18–21]. 
We recently demonstrated that cladosporol A, a secondary metabo-
lite from the fungus Cladosporium tenuissimum, exhibits antiproliferative 
properties in a variety of human colon cancer cell lines through PPARγ- 
mediated modulation of gene expression of several cell cycle gate-
keepers (p21waf1/cip1, cyclin D1, cyclin E, CDK2 and CDK4) [22,23]. 
These findings are consistent with results from the literature that PPARγ 
plays a protective role in in vitro and in vivo colorectal cancer (CRC) 
models [24,25]. We also investigated cladosporol B, an oxidised form of 
cladosporol A, and demonstrated that it is more efficient in inhibiting 
cell proliferation and inducing apoptosis in HT-29 cells, a CRC cell line. 
Cladosporol B acts as a PPARγ partial agonist, with lower affinity and 
reduced transactivation potential after transient transfection compared 
with the full agonists cladosporol A and rosiglitazone (RGZ, a TZD). 
Docking experiments provided the structural basis for full and partial 
PPARγ agonism of cladosporol A and B, respectively, confirming that the 
binding of cladosporol B is associated with a lower transactivation po-
tential, higher antiproliferative activity and more pronounced proapo-
ptotic activity compared with the two full agonists cladosporol A and 
RGZ [26]. 
We further investigated the properties of cladosporol A and clado-
sporol B in a different cellular context, namely the 3T3-L1 cell line, an in 
vitro model of preadipocytes. In this work, we demonstrated that cla-
dosporol A and cladosporol B inhibited adipogenesis in 3T3-L1 pre-
adipocytes that are committed to differentiate to mature adipocytes 
through an induction cocktail (3-isobutyl-1-methylxanthine, dexa-
methasone, insulin [MDI] and foetal bovine serum [FBS]) for 10 days. 
Using real-time polymerase chain reaction (PCR) and western blotting, 
we also verified that the mRNA and protein levels of early and late 
adipogenic markers were significantly reduced by treatment with cla-
dosporol A or cladosporol B. Finally, we demonstrated that culture 
medium from 3T3-L1 cells treated with cladosporol A or cladosporol B 
could inhibit proliferation and migration of HT-29 cells. These findings 
suggest a molecular mechanism by which dysregulated lipid metabolism 
and cancer promotion and progression could simultaneously be affected 
through the use of the same therapeutic tool. 
2. Materials and methods 
2.1. Cells, adipocyte differentiation and treatments 
Human colon adenocarcinoma HT-29 cells were obtained from the 
American Type Culture Collection (Rockville, MD). HT-29 cells bear a 
mutated p53 (p.Arg273His), but a wild-type ras allele. These cells were 
grown as a monolayer in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% FBS, 1% penicillin-streptomycin and 1% L-glutamine. 
The cells were cultured in 60 mm plates, to 70%–80% confluence, in a 
humidified atmosphere with 5% CO2. 
3T3-L1 cells were kindly provided by Prof. Beguinot (Department of 
Translational Medical Sciences, ‘Federico II’ University of Naples, Italy). 
To differentiate 3T3-L1 preadipocytes to mature adipocytes, 8.0 × 104 
cells were seeded in a 60 mm culture plate. After growth for two days to 
reach confluency (day 0 [D0]), the preadipocyte expansion medium 
(DMEM with 10% foetal calf serum [FCS]) was removed and 1-methyl-3- 
isobutylxanthine(IBMX), dexamethasone, and insulin (MDI)-induced 
adipocyte differentiation medium was added to the growth-arrested 
3T3-L1 preadipocytes. Cells were, indeed, cultured for 48 h with MDI 
containing DMEM (with 4.5 g/l glucose), 10% FBS, IBMX (0.5 mM), 
dexamethasone (1 μM) and insulin (1 μg/ml). Starting from day 2 (D2), 
cells were transferred to and cultured in the adipocyte maintenance 
medium containing DMEM (4.5 g/l glucose), 10% FBS and 1 μg/ml in-
sulin. This medium was changed every 48 h until day 8 (D8). 
Dr. Salvatore Moricca (Dipartimento di Scienze delle Produzioni 
Agroalimentari e dell’Ambiente (DiSPAA), Università degli Studi di 
Firenze, Piazzale delle Cascine 18, 50144 Firenze, Italy) isolated the 
fungus Cladosporium tenuissimum, while Dr. Sabrina Dallavalle (Dipar-
timento di Scienze per gli Alimenti, la Nutrizione e l’Ambiente, Uni-
versità degli Studi di Milano, via Celoria 2, 20133 Milano, Italy) purified 
and sent to us cladosporol A and cladosporol B [22]. 
Rosiglitazone (RGZ), cladosporol A, cladosporol B and GW9662 were 
dissolved in dimethyl sulphoxide (DMSO) and mixed with fresh medium 
to achieve the final concentration. In all treatments, the DMSO final 
concentration in the medium was less than 0.1%. RGZ, cladosporol A or 
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cladosporol B (5 μM) were added each time and the medium was 
replaced except for experiments where it was added only from D0 to D2 
or from D2 to D8. We preincubated 3T3-L1 preadipocytes for 3 h with 5 
μM GW9662. 
2.2. Antibodies and reagents 
Antibodies against PPARγ, C/EBPα, p21 and β-catenin were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
bodies against leptin, adiponectin, cyclin D1, caspase-3, β-actin and 
cyclophilin were purchased from Cell Signaling Technologies (Danvers, 
MA, USA). Anti-mouse and anti-rabbit IgG secondary antibodies con-
jugated to peroxidase as well as ECL and ECL Plus western blotting 
detection kits were purchased from Amersham Life Science (Little 
Chalfont, Buckinghamshire, UK). DMEM, RGZ, GW9662, IBMX, dexa-
methasone, insulin, Oil Red O and isopropanol were from Sigma Aldrich 
(St. Louis, MO, USA). FBS, penicillin-streptomycin, L-glutamine and 
trypsin-ethylenediaminetetraacetic acid (EDTA) were obtained from 
Gibco (Carlsbad, CA, USA). Lipofectamine 3000 Reagent was from 
Invitrogen (Carlsbad, CA, USA). 
PPARγ1/2 /E-8) Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
mw:57 kDa Dilution:1:1000 code: sc-7273. 
C/EBPα Santa Cruz Biotechnology (Santa Cruz, CA, USA) mw:42 
kDa Dilution: 1:1000. 
code: sc-365318. 
β-actin Cell Signaling Technologies (Danvers, MA, USA) mw: 45 kDa 
Dilution 1:1000. 
code: #3700. 
Leptin Abcam (Cambridge, UK) mw 16 kDa Dilution 1:1000 code: 
ab3583. 
Adiponectin Cell Signaling Technologies (Danvers, MA, USA) mw: 
27 kDa Dilution 1:1000 code:#2789. 
β-Catenin Santa Cruz Biotechnology (Santa Cruz, CA, USA) mw:105 
kDa Dilution 1:1000. 
code: sc-7963. 
Cyclin D1 Cell Signaling Technologies (Danvers, MA, USA) mw: 36 
kDa Dilution 1:1000. 
code: #2922. 
p-21 Santa Cruz Biotechnology (Santa Cruz, CA, USA) mw: 21 kDa 
Dilution 1:1000. 
code: sc-271610. 
Caspase 3 Cell Signaling Technologies (Danvers, MA, USA) mw: 35 
kDa Dilution 1:1000. 
code: #9662. 
2.3. Cell viability 
The growth rate of 3T3-L1 cells was evaluated using the MTT assay 
(Promega, Madison, WI, USA), as previously described [22]. To further 
evaluate cell growth after treatment with cladosporol A or cladosporol 
B, cells were plated in 12-well plates at density of 1 × 106 cells/cm2. 
After treatment, the cells were washed with phosphate-buffered saline 
(PBS), trypsinised and collected in culture medium. Cell counting was 
performed as previously reported [22]. 
2.4. Western blotting 
Treated and untreated cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.6, 10 mM 
EDTA, 1% NP-40) containing a protease inhibitor cocktail and then 
centrifugated at 17,000 g for 10 min at 4◦C. The protein concentrations 
of the supernatant was quantified and 80 μg of each sample were 
separated on 12% acrylamide gels using sodium dodecyl sulpha-
te–polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting 
was carried out as previously reported [22]. The relative intensity of 
protein bands was measured using the Molecular Imager Chemi-Doc 
imaging system and evaluated with ImageLab software (Bio-Rad, Her-
cules CA, USA) in comparison with the β-actin or cyclofillin used as 
control. The protein levels of extracellular leptin and adiponectin, re-
ported in Fig. 8B, were normalized in comparison with the total extra-
cellular proteins stained by the Ponceau dye. For each sample the same 
volume of extracellular total proteins was loaded. 
2.5. Oil Red O staining 
Oil Red O staining was performed by treating preadipocytes and 
mature 3T3-L1 adipocytes (after 8 days of differentiation) with 4% 
formaldehyde for 5 min at room temperature. The cells were washed 
with 1× PBS, incubated with 60% isopropanol for 5 min and dried 
completely. Fixed cells were stained with Oil Red O in 60% isopropanol 
for 1 h at room temperature. Stained lipid droplets in 3T3-L1 cells were 
imaged with a Nikon Eclipse TS100 microscope. Intracellularly stored 
lipids were quantified by extracting Oil Red O stain with 100% isopropyl 
alcohol; the optical density was measured at 500 nm by a Eppendorf 
BioPhotometer 6131. 
2.6. Semiquantitative reverse-transcriptase PCR and real-time PCR 
Total RNA was extracted from all experimental points of differenti-
ated and undifferentiated 3T3L1 cells using Trizol reagent according to 
the manufacturer’s instruction (Thermofisher, Whaltam, MA, USA). 
Total RNA was reverse transcribed to complementary DNA (cDNA) 
using a random hexadeoxynucleotide primer and reverse transcriptase. 
Single-stranded cDNA was amplified by PCR using specific primers. The 
primer sequences, the relative amplicon sizes and Gene ID are as follows: 
PPARγ2: 5′-TGGTGCCTTCGCTGATGC-3′ and 5′- 
CTGTGGTAAAGGGCTTGATGTC-3′; 
C/EBPα: 5′-CGACTTCTACGAGGTGGAGC-3′ and 5′-TCGATG-
TAGGCGCTGATGTC-3′; 
aP2: 5′-CACCATCCGGTCAGAGAGTACTTT-3′ and 5′-GCCATG-
TAGGGTTATGATGCTCTT-3′; 
LPL: 5′-GATGCCCTACAAAGTGTTCCATTA-3′ and 5′- 
CCACTGTGCCGTACAGAGAAAT-3′; 




Adiponectin: 5′-TCCGGGACTCTACTACTTCTCTTACCAC-3′ and 
5′GTCCCCATCCCCATACACCTG-3′; 
Leptin: 5′-TGACACCAAAACCCTCATCA-3′ and 5′-ATC-
CAGGCTCTCTGGCTTCT-3′; 
Perilipin: 5′- GCTCTTCAATACCCTCCAGAAAAG-3′ and 
5′-TTCGAAGGCGGGTAGAGATG-3′. 
Cyclophilin was used as internal control; the primer sequences are: 
5′-TTCCAGGATTCATGTGCCAG-3′ and 5′-CCATCCAGCCATT-
CAGTCTT-3′. 
PPARG2 Amplicon size 161 bp Gene ID: 19016 NM_011146.3. 
cEBPALPHA Amplicon size 195 bp Gene ID: 12606 
NM_001287514.1. 
AP2 Amplicon Size 147 bp Gene ID:11770 NM_024406.3. 
LPL Amplicon Size 107 bp Gene ID: 16956 NM_008509.2. 
FASN Amplicon size 190 bp Gene ID: 14104 NM_007988.3. 
GLUT 4 Amplicon size 98 bp Gene ID: 20528 NM_001359114.1. 
ADIPONECTIN Amplicon Size 199 bp Gene ID: 11450 NM_009605. 
LEPTIN Amplicon Size 310 bp Gene ID: 16846 NM_008493. 
CYCLOPHILIN (PPIA) Amplicon Size 202 bp Gene ID: 268373 
NM_008907.2. 
Semiquantitative reverse-transcriptase PCR was carried out by per-
forming 35 cycles (94 ◦C for 1 min, 54–64 ◦C for 30 s and 72 ◦C for 1 min, 
for each cycle). PCR products were analysed on 2% agarose gels con-
taining ethidium bromide. Gel images were acquired with the Chemi- 
Doc imaging system (Bio-Rad). To normalize the results cyclophilin 
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was used as reference gene. For real-time PCR assays, a 20 μl mixture 
containing 25 ng cDNA, 10 μl SYBR Green and 0.5 μM primers was 
prepared for each sample. All reactions were prepared using Quantifast 
SYBR Green PCR kit (Qiagen, Hilden, Germany) and performed ac-
cording manufacturer’s instructions. The assays were run on the CFX96 
Real-Time PCR Detection system (Bio-Rad) and evaluated with CFX 
Manager software. Cyclophilin was used as reference gene for relative 
quantification in real-time PCR experiments. 
2.7. Cell migration (wound healing) assay 
The migration ability of the HT-29 cells was investigated using a 
wound healing assay. Cells were seeded in 12-well plates at a subcon-
fluent density (8 × 104 cells/ml) in growth medium and were allowed to 
adhere overnight. Once the cells reached 100% confluence, a wound was 
formed using a plastic micropipette tip, and the conditioned medium 
from 3T3-L1 cells was used to culture HT-29 cells. Briefly, 3T3-L1 cells 
were differentiated as described in 2.1 and at day 8 (D8) medium from 
each different sample (MDI, MDI + RGZ, MDI + ClA, MDI-ClA, MDI +
ClB, MDI-ClB) was collected, filtered, concentrated through Amicon 
centrifugal filter unit Ultra 2 ml 10 K (Millipore Sigma MA, USA) and 
conserved at − 80 ◦C. This medium was used to evaluate HT-29 cell 
migration. Cell capacity to migrate was analysed by acquiring images of 
the scratch after formation (0 h), and 24, 48 and 72 h later. Images were 
captured using a Samsung Exinos 9 Octa 9820 camera attached to a 
Nikon TS2 microscope and quantified by Image J software. 
2.8. Transient transfection assays 
A plasmid bearing the PPRE (PPAR response element) motif for 
transfection assays in 3T3-L1 cells was a gift of Spiegelman’s group. This 
PPRE-Luc plasmid has a luciferase reporter gene under the transcrip-
tional control of the herpes simplex thymidine kinase (TK) promoter 
fused to three copies of the PPRE derived from Acyl-CoA oxidase gene. 
As an internal control for all transient transfection assays, we used the 
RSV-βGal plasmid, expressing β-galactosidase gene driven by the strong 
Rous Sarcoma Virus (RSV) promoter. After 2 days of expansion, 3T3-L1 
proliferating cells were transfected by Lipofectamine 3000 Reagent in 
accordance with the manufacturer’s instructions and after further 24 h 
treated with 5 μM RGZ, cladosporol A, cladosporol B, respectively. After 
48 h cells were collected, total protein extracts were produced and 
transactivation activities were evaluated by luciferase assay as previ-
ously described [26]. The values were normalized by β-galactosidase 
assay and the average value for each triplicate was calculated. The same 
protocol of transfection assay was performed to evaluate the trans-
activation activities in 3T3-L1 mature adipocytes. After the transfection, 
preadipocytes were cultured for further two days in differentiation 
medium (MDI) plus RGZ, cladosporol A, cladosporol B, respectively. 
3T3-L1 preadipocytes and mature adipocytes were also pretreated (in 
the indicated samples of Fig. 5F and G) with 5 μM of GW9662 before the 
addition of 5 μM RGZ, 5 μM cladosporol A, 5 μM cladosporol B, 
respectively. Transfection samples were carried out in triplicate and the 
transactivation activities evaluated by luciferase assay. The values were 
normalized by β-galactosidase assay and the average value for each 
triplicate was calculated. 
2.9. Statistical procedures 
All experiments were performed in duplicate or triplicate with at 
least two biological replicates and data are expressed as the mean ±
standard deviation calculated by Graphpad Prism software. Differences 
between two groups were assessed using Student’s t-test. Differences 
between three or more groups were assessed using a one-way analysis of 
variance (ANOVA). Asterisks reported in the figure show the degree of 
statistical significance. A P value <0.05 was considered significant. 
3. Results 
3.1. Cladosporol A and cladosporol B inhibited the in vitro adipogenesis 
of 3T3-L1 cells 
To determine whether cladosporol A and cladosporol B display 
antiproliferative activity towards 3T3-L1 preadipocytes, we first evalu-
ated the growth of these cells treated for different time points (24 and 
48 h) with increasing concentrations of the compounds (1, 5, 10 and 20 
μM). There was not a significant reduction in the number of surviving 
cells after treatment with 1, 5 or 10 μM cladosporol A or cladosporol B 
for 24 or 48 h (Fig. 1A). There was a partial growth inhibition of 3T3-L1 
preadipocytes (about 30% in the presence of cladosporol A and 20% in 
the presence of cladosporol B) only at the highest concentration (20 μM) 
and mostly after 48 h exposure. The same treatment times and doses of 
rosiglitazone (RGZ), a well-known full agonist of PPARγ, did not 
appreciably reduce the number of 3T3-L1 preadipocytes. To further 
confirm these data, we subsequently treated 3T3-L1 preadipocytes as 
described above and evaluated the cytotoxic potential of cladosporol A 
and cladosporol B using the MTT assay. There was a decrease in 3T3-L1 
preadipocyte viability only after exposure to the highest concentration 
(20 μM) of cladosporol A (about 20% and 33% after 24 and 48 h, 
respectively) and cladosporol B (about 17% and 23% after 24 and 48 h, 
respectively) (Fig. 1B). The same doses of RGZ did not affect the 3T3-L1 
preadipocyte viability. We previously demonstrated that exposure of 
HT-29 cells to 10 μM cladosporol B for 48 h inhibited cell proliferation 
by about 90% [26]. In this study, the administration of cladosporol A or 
cladosporol B at concentrations below 20 μM did not affect the prolif-
eration of 3T3-L1 preadipocytes. On basis of these data, unless specif-
ically indicated, we used doses ≤10 μM cladosporol A or cladosporol B in 
the subsequent assays. 
We next investigated 3T3-L1 preadipocyte differentiation. The cells 
were treated with MDI plus 5 μM RGZ, cladosporol A or cladosporol B, 
respectively (see Fig. 2A) and then stained with Oil Red O after 10 days 
of differentiation. As shown in Fig. 2B and D, accumulation of lipid 
droplets was strongly evident in cells treated with 1-methyl-3-isobutyl-
xanthine(IBMX), dexamethasone, and insulin (MDI) or MDI plus RGZ, 
thus suggesting that morphological and functional changes were asso-
ciated with differentiation of 3T3-L1 preadipocytes to mature adipo-
cytes. On the contrary, exposure to MDI plus cladosporol A or 
cladosporol B appeared to inhibit lipid accumulation, thus indicating 
that both molecules impaired adipogenesis. Fig. 2E shows the quanti-
tative evaluation of the Oil Red O–stained cells through spectrophoto-
metric analysis at 500 nm. Treatment with MDI plus 5 μM cladosporol A 
or cladosporol B inhibited lipid storage in the mature adipocytes 
compared with treatment with MDI or MDI plus RGZ. Based on the 
viability and differentiation data (Figs. 1 and 2), we can confirm that the 
antiadipogenic activity of both cladosporol A and cladosporol B is not 
dependent on a general cytotoxicity. 
3.2. Cladosporol A and cladosporol B downregulated the expression of 
adipogenesis-specific genes in 3T3-L1 cells 
To clarify the molecular mechanisms underlying the inhibitory ef-
fects of cladosporol A and cladosporol B on adipogenesis in 3T3-L1 cells, 
we performed semiquantitative reverse-transcriptase PCR on total 
mRNA extracted from 3T3-L1 preadipocytes after 3 and 10 days of 
treatment with MDI plus 5 μM RGZ or 5 μM cladosporol A or 5 μM 
cladosporol B, respectively. PPARγ and C/EBPα mRNA levels were 
significantly increased during the early stages of adipogenesis (within 3 
days) when treated with MDI or MDI plus RGZ (Fig. 3A). Administration 
of MDI plus cladosporol A or cladosporol B, on the contrary, caused a 
noticeable reduction in both of these early adipogenic markers. After 10 
days of differentiation, although the basal PPARγ2 and C/EBPα mRNA 
levels appeared to be quite different, exposure of the mature adipocytes 
to cladosporol A or cladosporol B also induced an evident reduction in 
R. Rapuano et al.                                                                                                                                                                                                                               
BBA - General Subjects 1865 (2021) 129973
5
(caption on next page) 
R. Rapuano et al.                                                                                                                                                                                                                               
BBA - General Subjects 1865 (2021) 129973
6
both markers. PPARγ2 and C/EBPα play a central role in inducing adi-
pogenesis because their overexpression positively regulates genes 
required for the terminal differentiation phase of adipogenesis, such as 
FASN, aP2, LPL and GLUT4. Although the basal levels of these terminal 
differentiation markers of functional adipocytes are different, their 
expression was clearly affected by the administration of MDI plus either 
cladosporol compared with the cells treated with MDI or MDI plus RGZ 
(Fig. 3A). Mature adipocytes usually secrete several endocrine signals to 
participate in caloric homeostasis. Thus, we next examined whether 
leptin and adiponectin expression was affected by the administration of 
cladosporol A or cladosporol B during the terminal differentiation of 
3T3-L1 cells. Leptin and adiponectin mRNA levels in 3T3-L1 mature 
adipocytes were significantly decreased after treatment with clado-
sporol A or cladosporol B, indicating a strong inhibition of adipogenesis 
(Fig. 3A). 
We confirmed the semiquantitative data with real-time PCR, using 
total RNA extracted from 3T3-L1 adipocytes. As expected, expression of 
the two early adipogenesis-related genes, PPARγ and C/EBPα, was 
significantly reduced after treatment with MDI plus 5 μM cladosporol A 
or cladosporol B for 3 days (Fig. 3B). Furthermore, the mRNA level of 
four of terminal differentiation markers (aP2, FASN, adiponectin and 
perilipin) was diminished when the cells were treated with MDI plus 5 
μM cladosporol A or cladosporol B for 10 days, compared with cells 
treated with MDI or MDI plus RGZ (Fig. 3C). 
We also analysed by western blotting the protein levels of the same 
markers for which we examined transcript levels. The two early 
markers, PPARγ and C/EBPα (Fig. 4А), and the two terminal differen-
tiation markers, leptin and adiponectin (Fig. 4B), were downregulated in 
the presence of MDI plus 5 μM cladosporol A or cladosporol B compared 
with cells treated with MDI or MDI plus RGZ. Our gene and protein 
expression results suggest that cladosporol A and cladosporol B inhibited 
adipogenesis in 3T3-L1 cells by reducing the mRNA and protein levels of 
early and terminal differentiation markers of adipogenesis. 
3.3. Cladosporol A and cladosporol B displayed PPARγ-mediated 
antiadipogenic activity 
To demonstrate definitively that PPARγ mediates the antiadipogenic 
signals of the cladosporols, we preincubated 3T3-L1 preadipocytes for 3 
h with 5 μM GW9662, a well-known irreversible inhibitor of PPARγ, and 
subsequently treated cells with MDI or MDI plus 5 μM RGZ, cladosporol 
A or cladosporol B, respectively. We allowed the cells to differentiate 
until up to 10 days and then stained them with Oil Red O to evaluate the 
accumulation of intracellular lipids. Results of Fig. 5A demonstrated that 
preincubation of 3T3-L1 cells with 5 μM GW9662 caused a significant 
decrease of lipid depots in all the tested conditions (MDI, MDI plus RGZ, 
MDI plus cladosporol A and MDI plus cladosporol B), suggesting that this 
specific irreversible inhibitor subtracted a part of the available and 
functional PPARγ. Data from Fig. 5B, showing the quantitative evalua-
tion of the Oil Red O–stained cells through spectrophotometric analysis 
at 500 nm, confirmed the diminished ability of the mature adipocytes to 
accumulate lipids when the cells were pretreated with GW9662. To 
verify that pretreatment with GW9662 impaired the binding to PPARγ of 
the other ligands and, in such way, triggered the receptor degradation, 
we preincubated 3T3-L1 preadipocytes with 5 μM GW9662 and ana-
lysed by western blotting PPARγ expression in cells successively exposed 
to MDI, MDI plus 5 μM RGZ, MDI plus 5 μM cladosporol A and MDI plus 
5 μM cladosporol B. Results from Fig. 5C demonstrated that GW9662 
pretreatment caused a reduction in PPARγ expression in all tested con-
ditions. These data suggested that this inhibitor, that covalently binds to 
the PPARγ ligand binding domain (LBD) pocket, may sequester func-
tional and available receptor so that it cannot bind to the tested ligands 
(RGZ, cladosporol A and cladosporol B). Moreover, it is remarkable that 
expression of both PPARγ1 and PPARγ2 (the adipogenic specific isoform 
containing about 30 additional amino acids at the N-terminus) was 
affected by GW9662 binding, thus preventing the specific interaction 
with the tested ligands (RGZ, cladosporol A and cladosporol B). In order 
to further confirm that cladosporol action was mediated by the binding 
to PPARγ, we transiently transfected 3T3-L1 preadipocytes with a 
plasmid bearing the PPRE (PPAR response element) motif cloned up-
stream the basal TK promoter that, in turn, drives the transcription of 
luciferase reporter gene. As shown in Fig. 5D, the transcriptional ac-
tivity, promoted by the PPRE motif cloned upstream the luciferase gene, 
was induced by the canonical agonist of PPARγ, RGZ, whereas was 
inhibited by both cladosporols. At the same time, we transfected another 
aliquot of 3T3-L1 preadipocytes and, afterwards, allowed these cells to 
differentiate to mature adipocytes by MDI treatment. The results of 
Fig. 5E indicated that the transcription of luciferase reporter gene, 
driven by PPRE motif cloned upstream the basal TK promoter, was 
further increased by RGZ treatment and again inhibited by both clado-
sporols. Note the maior increase (2.0 vs 1.5 of arbitrary units) of lucif-
erase gene transcription due to RGZ, when the level of PPARγ expression 
was induced after at least two days of differentiation through MDI 
treatment (compare sample 3 of Fig. 5D with sample 3 of Fig. 5E). To 
demonstrate that binding of cladosporols to PPARγ is the unique con-
dition to permit their action, we repeated the transient transfection as-
says in preadipocytes (Fig. 5F) and in preadipocytes that were 
differentiated to mature adipocytes (Fig. 5G) in presence and absence of 
GW9662. Data from these experiments suggested that 5 μM GW9662 
pretreatment of both preadipocytes and mature adipocytes caused a 
reduction of the transcription activity driven by the PPRE motif in all 
tested conditions (MDI, MDI plus RGZ, MDI plus cladosporol A and MDI 
plus cladosporol B). Altogether the experiments of Fig. 5 indicate that 
binding of cladosporols to PPARγ, the master regulatory gene of adi-
pogenesis, is a crucial part of the mechanism by which they inhibit 
adipogenesis in 3 T3-L1 cells. 
3.4. The antiadipogenic activity of cladosporols A and B influenced the 
proliferation and invasion of HT-29 cells 
Because adipose tissue plays a prominent role in the tumour micro-
environment, we decided to investigate whether secreted factors (adi-
pokines) from 3T3-L1 cells could influence HT-29 cell growth, invasion 
and migration. Hence, we allowed 3T3-L1 preadipocytes to differentiate 
(see section 2.1) and collected the medium from cells treated with MDI, 
MDI plus 5 μM RGZ, 5 μM cladosporol A or 5 μM cladosporol B, 
respectively. The medium was filtered and used as conditioned medium 
to examine the effect on HT-29 cell proliferation. The conditioned me-
dium collected from 3T3-L1 cells treated with MDI plus cladosporol A or 
cladosporol B inhibited HT-29 cell proliferation. On the contrary, the 
conditioned medium from 3T3-L1 treated with only MDI or (to a greater 
extent) from undifferentiated preadipocytes appeared to permit cell 
proliferation. The inhibitory effects due to the conditioned medium from 
3T3-L1 treated with MDI plus both cladosporols were already evident 
Fig. 1. Treatment with cladosporol A or cladosporol B did not affect 3T3-L1 preadipocyte proliferation. (A) The antiproliferative effects of rosiglitazone (RGZ), 
cladosporol A (CL A) and cladosporol B (CL B) on exponentially growing 3T3-L1 cells: cells were treated or not treated with 1, 5, 10 and 20 μM of the compounds for 
24 and 48 h, collected and counted. The data are presented as the mean ± standard deviation of three experiments performed in duplicate. The results were similar in 
two independent experiments. *P < 0.05 and **P < 0.01, compared with control (Ctrl), the untreated preadipocytes. (B) Dose-dependent 3T3-L1 cytotoxicity caused 
by RGZ, CL A and CL B, as determined by the MTT assay. Cells were seeded in 96-well plates at a density of 6.0 × 104 cells/cm2 in standard conditions. After 24 h, 
cells were exposed to increasing concentrations of RGZ, CL A or CL B (from 1 to 20 μM) and the growth was evaluated up to 24 and 48 h by measuring the absorbance 
at 590 nm. The results are expressed as the optical density ratio of the difference between treated and control cells. Each point was performed in triplicate and the 
experiment was repeated two times. *P < 0.05 and **P < 0.01, compared with Ctrl, the untreated preadipocytes. 
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Fig. 2. Cladosporol A and cladosporol B inhibited 3T3-L1 differentiation. (A) Scheme of 3T3-L1 preadipocyte differentiation and cladosporol treatments. (B) Cells 
were treated for 10 days with the differentiation mixture (MDI), MDI plus 5 μM rosiglitazone (MDI + RGZ) or MDI plus 5 μM cladosporol A (MDI + CL A) or MDI plus 
5 μM cladosporol B (MDI + CL B) and then stained with Oil Red O. (C) Cells were also stained with hematoxylin to visualise the nuclei. (D) Photographs of the same 
cells in the Petri dishes treated as described in (B). (E) The graph shows the quantitative evaluation of Oil Red O staining. The data are presented as the mean ±
standard deviation of two different experiments performed in duplicate. The untreated preadipocytes were the control cells. 
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after 48 h (Fig. 6A), while the reduction in the number of HT-29 cells 
was even more dramatic after 72 h (Fig. 6B). 
To determine the effects of 3T3-L1 conditioned medium on HT-29 
cell migration, we carried out a wound healing assay (see details in 
section 2.6; Fig. 7). We captured images at 0, 48 and 72 h after wound 
formation to determine the degree of healing. Conditioned medium from 
3T3-L1 preadipocytes and differentiated adipocytes (treated with MDI) 
significantly enhanced the migratory ability of HT-29 cells. On the 
contrary, migration of the cells was significantly inhibited after expo-
sure to conditioned medium collected from 3T3-L1 cells treated with 
MDI plus cladosporol A or cladosporol B (Fig. 7A). The migratory ability 
of cells was only partially affected by the conditioned medium collected 
from 3T3-L1 cells treated with MDI plus RGZ. We repeated the above 
described experiment, modifying the protocol as indicated in Fig. 7B. 
The conditioned medium collected from 3T3-L1 cells treated with MDI 
plus cladosporol A or cladosporol B was deprived of both drugs during 
the last two days of cell differentiation (the new samples are denoted as 
MDI-CL A and MDI-CL B in Fig. 7B and C). We deemed this protocol 
variation necessary to determine whether the inhibition of cell migra-
tion could be attributed to the effects of cladosporols on 3T3-L1 
adipocyte differentiation and not directly to the presence of the drugs in 
the conditioned medium. In these new experimental conditions, condi-
tioned medium from 3T3-L1 cells treated with MDI plus cladosporol A or 
cladosporol B provided the same inhibition of HT-29 proliferation and 
migration (Fig. 7C). To demonstrate definitively the inhibitory effects on 
HT-29 cell growth and migration, we used western blotting assay of the 
total protein extracted from HT-29 cells treated with the medium from 
preadipocytes, 3T3-L1 treated with MDI or 3T3-L1 treated with MDI 
plus RGZ, cladosporol A or cladosporol B, respectively. There was an 
evident reduction in cyclin D1 and β-catenin and a simultaneous in-
crease in p21 expression, thus suggesting a strong blockage of cell cycle 
of HT-29 cells grown with the conditioned medium from cells exposed to 
either cladosporol (Fig. 7D). Moreover, there was a significant stimu-
lation of apoptosis: the same conditioned medium from cells exposed to 
either cladosporol reduced caspase-3 precursor levels, one of the ter-
minal effectors of programmed cellular death. 
Leptin and adiponectin are two adipokines produced by mature ad-
ipose tissue to integrate peripheral and central signals, but they also 
represent components of the milieu that stimulate the tumour micro-
environment and thus regulate signaling pathways related to cancer 
Fig. 3. Cladosporol A and cladosporol B downregulated the expression of adipogenesis-related genes in 3T3-L1 cells. (A) Semiquantitative reverse-transcriptase 
polymerase chain reaction (PCR) analysis of early (3 days) and late (10 days) adipogenic markers in 3T3-L1 cells. The template for complementary DNA (cDNA) 
was total RNA extracted from cells treated with the differentiation mixture (MDI), MDI plus 5 μM rosiglitazone (MDI + RGZ) or MDI plus 5 μM cladosporol A (MDI +
CL A) or MDI plus 5 μM cladosporol B (MDI + CL B). The untreated preadipocytes (3T3-L1) were the control cells.The expression values were normalized using as 
control the cyclophilin gene product. The data are presented as the mean ± standard deviation of two different experiments performed in duplicate. (B) Real-time 
PCR analysis of mRNA levels of early adipogenesis-related genes (PPARγ and C/EBPα) in 3T3-L1 cells. The template for complementary DNA was total RNA extracted 
from cells treated with MDI, MDI plus 5 μM rosiglitazone (MDI + RGZ) or MDI plus 5 μM cladosporol A (MDI + CL A) or MDI plus 5 μM cladosporol B (MDI + CL B). 
The expression values were normalized using as control the cyclophilin gene product. The data are presented as the mean ± standard deviation of three experiments 
performed in triplicate. *P < 0.05, **P < 0.01 and ***P < 0.001, compared with Ctrl (3T3-L1). (C) Real-time PCR analysis of mRNA levels of late adipogenesis- 
related genes (aP2, FASN, adiponectin and perilipin) in 3T3-L1 cells. The details are the same as described in (B). *P < 0.05, compared with Ctrl (3T3-L1). 
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progression [27–30]. Therefore, we analysed the presence of these 
important adipokines in 3T3-L1 cells and in the culture medium of un-
differentiated and differentiated 3T3-L1 cells treated with MDI plus 
RGZ, cladosporol A or cladosporol B, respectively. Both cladosporols 
reduced the leptin expression level in cells and in the medium (Fig. 8A 
and B). On the contrary, leptin expression was higher in the 3T3-L1 
preadipocytes as well as in the medium from differentiated 3T3-L1 
cells treated with MDI or MDI with RGZ. Both cladosporols reduced 
adiponectin expression in the cells but stimulated adiponectin secretion 
in the medium (Fig. 8A and B). Collectively, these results strongly sug-
gest that cladosporols are able to regulate production and availability of 
the most important hormones that differentiated adipocytes secrete in 
order to influence biological properties of neighbouring cells. 
4. Discussion 
Obesity, insulin resistance, type 2 diabetes and cardiovascular dis-
eases constitute the most frequent pathological conditions associated 
with metabolic syndrome, an epidemic that affects a quarter of the 
world’s population. Excessive nutrient intake and very low calorie 
expenditure due to a limited physical activity appear to be the possible 
causes of the impressive spread of metabolic syndrome all over the 
world [31]. Therefore, metabolic syndrome can be considered the result 
of an imbalance between the storage of energy fuels and their utilisation. 
Distinctive clinical signs of metabolic syndrome are abdominal obesity, 
hypertension, dyslipidaemia, insulin resistance and a proinflammatory 
state [32]. The most recent findings have demonstrated that patients 
affected by metabolic syndrome can also develop – in addition to car-
diovascular diseases, diabetes and obesity – fatty liver, cholesterol 
Fig. 3. (continued). 
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gallstones and some types of cancer, including pancreatic, breast, 
bladder and colorectal [33]. To manage efficiently not only cancer, but 
also metabolic syndrome and its related consequences (obesity, hyper-
tension, dyslipidaemia, insulin resistance and cardiovascular diseases), 
a dual approach has been proposed: lifestyle modification (stimulating 
physical activity and diminishing food intake) and efficient chemopre-
vention using natural and/or synthetic compounds. This dual inter-
vention should ameliorate systemic metabolic dysfunctions by targeting 
insulin resistance, obesity, hypertension, hyperglycaemia, dyslipidae-
mia and inflammation, thus simultaneously reducing several risk factors 
Fig. 4. Cladosporol A and cladosporol B downregulated the expression of adipogenesis-related proteins in 3T3-L1 cells. (A) Western blotting analysis of early 
adipogenesis-related proteins in 3T3-L1 cells. Total protein from 3T3-L1 cells treated with differentiation mix (MDI) or MDI plus 5 μM rosiglitazone (RGZ) or 5 μM 
cladosporol A (CLADO A) or 5 μM cladosporol B (CLADO B) were separated by sodium dodecyl sulfate–polyacrylamide gel electropheresis and transferred to nylon 
membranes. Subsequently, antibodies were used to detect the expression of PPARγ and C/EBPα. The left part of figure shows a representative experiment, whereas 
the right part of the figure shows the quantitative evaluation of protein levels of both markers. To control the samples loaded derived from untreated and cladosporol 
A- and cladosporol B-treated 3T3-L1 cells and normalize the results, an anti-β-actin antibody was used. The bar graphs represent the mean ± SD of protein/β-actin of 
at least 3 independent experiments **P < 0.01 and ***P < 0.001, compared with control (3T3-L1). (B) Western blotting analysis of of late adipogenesis-related 
proteins in 3T3-L1 cells. Description of the assay is as in (A). Specific antibodies were used to detect the expression of leptin and adiponectin. The details of the 
evaluation also are the same as described in (A). *P < 0.05 and ***P < 0.001, compared with control (3T3-L1). 
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Fig. 5. PPARγ mediated the antiadipogenic effect of cladosporols. (A) 3T3-L1 cells, after 2 days of expansion, were firstly exposed for three hours to GW9662 (5 μM) 
and then treated for 10 days with the differentiation mixture MDI (GW + MDI), MDI plus 5 μM rosiglitazone (GW + MDI + RGZ) or MDI plus 5 μM cladosporol A 
(GW + MDI + CL A) or MDI plus 5 μM cladosporol B (GW + MDI + CL B). Samples from no pretreated cells with GW9662 are denoted with MDI, MDI + RGZ, MDI +
CL A, MDI + CL B. Successively, they were stained with Oil Red O. Photographs of the same cells in the Petri dishes treated as described in (A) are also shown. (B) The 
graph shows the quantitative evaluation of Oil Red O staining. The data are presented as the mean ± standard deviation of two different experiments performed in 
duplicate. The untreated preadipocytes 3T3-L1 were the control cells. (C) Western blotting analysis of PPARγ1 and PPARγ2 protein levels. Total protein was extracted 
from untreated 3T3-L1 cells and 3T3-L1 cells treated with differentiation mix (MDI) or MDI plus rosiglitazone (RGZ), cladosporol A (CL A) or cladosporol B (CL B), in 
the presence or absence of GW9662. Proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to nylon membranes. 
Subsequently, antibodies were used to detect the expression of PPARγ1 and PPARγ2. To control the samples loaded derived from untreated and cladosporol A- and 
cladosporol B-treated 3T3-L1 cells and normalize the results, an anti-β-actin antibody was used. The bar graphs represent the mean ± SD of protein/β-actin of at least 
3 independent experiments.*P < 0.05, **P < 0.01 and ***P < 0.001, compared with control (Ctrl). (D) Transient transfection assay performed in 3T3-L1 pre-
adipocytes. A plasmid bearing the PPRE (PPAR response element) motif cloned upstream the basal TK promoter that, in turn, drives the transcription of luciferase 
reporter gene was transfected in 3T3-L1 proliferating cells and, subsequently, treated with RGZ, cladosporol A, cladosporol B, respectively. The data are presented as 
the mean ± standard deviation of two different experiments performed in triplicate. ***P < 0.0002, compared with transfected but non treated cells used as control 
(sample 1 of Fig. 5D). (E) Transient transfection assay performed in 3T3-L1 mature adipocytes. The same protocol of transfection assay was performed, but the 
preadipocytes, after the transfection, were cultured in differentiation medium (in presence of MDI) plus RGZ, cladosporol A, cladosporol B, respectively. The data are 
presented as the mean ± standard deviation of two different experiments performed in triplicate. ****P < 0.0001, compared with transfected but non treated cells 
used as control (sample 1 of Fig. 5E). (F) Transient transfection assay performed in 3T3-L1 preadipocytes in presence and absence of GW9662. The protocol of 
transfection assay was the same of (D), but the transfected preadipocytes were firstly pretreated for 3 h with 5 μM of GW9662 and then exposed to the differentiation 
mixture (MDI) plus 5 μM rosiglitazone (RGZ) or 5 μM cladosporol A (CL A) or 5 μM cladosporol B (CL B). The data are presented as the mean ± standard deviation of 
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of cancer. 
In recent studies, we focused on the role of cladosporols, secondary 
metabolites derived from C. tenuissimum, in controlling CRC cell prolif-
eration [22,23,26]. Cladosporols exert this function by acting as ligands 
of PPARγ, one of the PPAR isoforms. PPARs, which are type II nuclear 
receptors, regulate a wide range of biological processes, including 
glucose and lipid metabolism, differentiation, cell growth and inflam-
mation, in different tissues. A relationship between adipogenesis and 
cancer progression has been demonstrated [34]; hence, we wanted to 
investigate whether cladosporols, as PPARγ ligands that interfere with 
two relevant pathological processes – lipid dysregulation and increased 
cell proliferation – could be efficient therapeutic tools to control meta-
bolism and cancer and thus simultaneously prevent obesity and cancer. 
Cladosporol A and cladosporol B inhibited adipogenesis in 3T3-L1 cells, 
reducing accumulation of fatty acids that are then transformed to tri-
glycerides in mature adipocytes (Fig. 2). Both cladosporols interfered 
with adipogenesis, denoted by decreased mRNA and protein expression 
of early and late adipogenic markers (Figs. 3 and 4). Among these dif-
ferentiation markers, PPARγ plays a crucial, master regulatory role in 
stimulating adipogenesis, and the inhibitory effect promoted by both 
cladosporols on PPARγ mRNA and protein expression is dramatic 
(Figs. 3A, Figs. 3B and 4A). Western blotting unequivocally confirmed 
that cladosporol A and cladosporol B activity in 3T3-L1 cells depends on 
binding to PPARγ. Indeed, pretreatment of these cells with GW9662, an 
irreversible inhibitor of PPARγ, reduced the expression of both isoforms 
(PPARγ1 and PPARγ2) in cells treated with cladosporol A or cladosporol 
B thus causing also an inhibitory effect on the 3T3-L1 cell differentiation 
and lipid accumulation (Fig. 5A, B and C). Transient transfection assays, 
two different experiments performed in duplicate. The data were normalized with transfected but non treated cells used as control (sample 1 of Fig. 5F). (G) Transient 
transfection assay performed in 3T3-L1 mature adipocytes in presence and absence of GW9662. The protocol of transfection assay was the same of (E), but the 
transfected preadipocytes were firstly pretreated for 3 h with 5 μM of GW9662 and then exposed to the differentiation mixture (MDI) plus 5 μM rosiglitazone (RGZ) 
or 5 μM cladosporol A (CL A) or 5 μM cladosporol B (CL B). The data are presented as the mean ± standard deviation of two different experiments performed in 
duplicate. The data were normalized with transfected but non treated cells used as control (sample 1 of Fig. 5G). 
Fig. 5. (continued). 
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reported in Fig. 5D-G, further proved that cladosporol action required its 
binding to PPARγ. These data are consistent with those from our pre-
vious papers in which we demonstrated that the antiproliferative and 
proapoptotic activities of cladosporols against CRC-derived cells are 
mediated by binding of both these drugs to PPARγ [22,23,26]. 
It is intriguing to compare the cladosporol-mediated effects with the 
effects of RGZ, a well-known full agonist of PPARγ belonging to the TZD 
family. While RGZ strongly activated PPARγ, thus inducing differenti-
ation of 3T3-L1 preadipocytes to mature adipocytes, both cladosporols, 
on the contrary, displayed a robust inhibition of PPARγ activity and an 
evident ability to arrest the differentiation process in the early phase 
(Fig. 2). RGZ has been identified as a full agonist of PPARγ, and in this 
role it is able to enter the PPARγ LBD pocket, where it binds to the 
specific functional group of some exposed amino acids. Specifically, RGZ 
forms canonical hydrogen bonds with residues Y473, H449 and H327 on 
the inner surface of H12, and stabilises the region, including loop 11/12, 
thus contributing to establish the network of contacts required for the 
activation of H12 that, in turn, allows recruitment of coactivators [35]. 
The data from our previous studies demonstrated that cladosporol A 
binds to the PPARγ pocket differently from RGZ, but it still behaves like 
a full agonist. In addition, we found that cladosporol B binds to the LBD 
pocket even more differently [26]. Interestingly, cladosporol B makes no 
direct contacts with H12, a hallmark of traditional TZDs, but preferen-
tially stabilises H3 through closer hydrophobic contacts or hydrogen 
bonds with residues of this helix (S289, F282, Q283 and Q286). These 
contacts likely affect the recruitment of specific cofactors and generate a 
different transactivation potential [26]. On the basis of the experiments 
carried out in these previous studies, we affirmed that cladosporol A 
works as a peculiar PPARγ full agonist, whereas cladosporol B is a proper 
partial agonist of PPARγ [36]. On the strength and specificity of these 
diverse modes of binding of cladosporol A and cladosporol B, we suggest 
that both these drugs specifically induce, in the milieu of 3T3-L1 cells 
committed to differentiate to mature adipocytes, changes in the PPARγ 
LBD structure that cause the recruitment of different cofactors. Thus, 
cladosporol A and cladosporol B might inhibit particular differentiation 
pathways in 3T3-L1 cells and ultimately mediate the antiadipogenic 
function. 
Adipose tissue is an endocrine organ that can synthesise and secrete 
several adipocytokines that are involved in the control of energy ho-
meostasis [37]. An increase in adipose tissue results in adipocytokine 
dysregulation that, in turn, causes serious metabolic diseases [38]. 
Adiponectin, an adipocytokine, is usually synthesised in mature adipo-
cytes and secreted in the blood to stimulate insulin action [39]. The 
plasma adiponectin level in obese animal models and human patients is 
very low; this phenomenon indicates that a reduced concentration of 
adiponectin might cause development of obesity-dependent metabolic 
complications such as type 2 diabetes [40,41]. Diminished plasma adi-
ponectin levels during tumour development in different tissues have 
been observed [42–44]. Moreover, various studies have demonstrated 
there is a close correlation between low levels of plasma adiponectin and 
the risk of colon cancer [45,46]. Finally, it is well known that adipo-
nectin exerts antiproliferative and proapoptotic activities on CRC- 
derived cells [47]. Adipocytes regulate the tumour microenvironment 
by secreting adipokines to modify cancer promotion and progression. 
Hence, we wondered whether factors secreted by undifferentiated and 
differentiated 3T3-L1 cells treated with MDI plus cladosporol A or cla-
dosporol B could influence the growth and migration of HT-29 cells. 
There was evident inhibition of HT-29 proliferation and migration when 
these cells were cultured with conditioned medium from differentiated 
3T3-L1 cells treated with MDI plus cladosporol A or cladosporol B 
compared with the controls (undifferentiated preadipocytes and differ-
entiated 3T3-L1 cells treated with MDI plus RGZ) (Figs. 6 and 7). These 
data suggest a cladosporol-treatment-dependent break in the crosstalk 
between 3T3-L1 mature adipocytes and HT-29 cells. Inhibition of 
growth and migration of HT-29 cells appears to be induced by increased 
adiponectin synthesis and secretion in the medium from differentiated 
3T3-L1 cells treated with MDI plus cladosporol A or cladosporol B 
compared with the controls (undifferentiated preadipocytes and differ-
entiated 3T3-L1 cells treated with MDI plus RGZ) (Fig. 8A and B). The 
elevated adiponectin protein level in the conditioned medium from 
differentiated 3T3-L1 cells treated with MDI plus cladosporol A or cla-
dosporol B was also accompanied by diminished leptin synthesis and 
secretion (Fig. 8A and B). It is well known that leptin works as a mito-
genic and antiapoptotic factor towards CRC-derived cells, whereas adi-
ponectin displays robust antiproliferative and proapoptotic activities in 
the same kind of cells [48–50]. We demonstrated that cladosporols can 
differentially modulate adiponectin and leptin expression and their 
secretion in the medium, thus suggesting that both drugs could interfere 
with the relative pathways induced by these adipocytokines. It is 
reasonable that the simultaneous decrease of leptin and the increase of 
adiponectin in the medium, collected from differentiated 3T3-L1 cells 
treated with MDI plus cladosporol A or cladosporol B, may mediate the 
inhibitory effects on HT-29 cell proliferation and migration (Fig. 7D). 
In conclusion, our findings confirm the role of cladosporols as spe-
cific inhibitors of mature adipocyte differentiation. Both cladosporol A 
and cladosporol B inhibited the expression of adipogenesis-related 
Fig. 6. Conditioned medium from 3T3-L1 
cells treated with cladosporol A or clado-
sporal B inhibited HT-29 proliferation. 3T3- 
L1 cells were differentiated as described in 
section 2.1, and the medium of cells (CM) 
treated with MDI, MDI plus 5 μM rosiglita-
zone (MDI + RGZ) or MDI plus 5 μM cla-
dosporol A (MDI + CL A) or MDI plus 5 μM 
cladosporol B (MDI + CL B) was collected, 
used to culture HT-29 cells for 48 h (A) and 
72 h (B) and finally counted. The data are 
presented as the mean ± standard deviation 
of two different experiments performed in 
triplicate.   
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Fig. 7. Conditioned medium from 3T3-L1 cells treated with cladosporol A or cladosporol B inhibited HT-29 migration and invasion. (A) 3T3-L1 preadipocytes were 
differentiated as described in section 2.1, and the medium from cells treated with MDI, MDI plus 5 μM rosiglitazone (MDI + RGZ) or MDI plus 5 μM cladosporol A 
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(MDI + CL A) or MDI plus 5 μM cladosporol B (MDI + CL B) was collected. HT-29 cells were plated at a subconfluent density (8.0 × 104 cells/ml) in growth medium. 
Once they reached 100% confluence, a wound was formed using the plastic micropipette tip. Conditioned medium was used to culture HT-29 cells for 48 and 72 h. 
(B) The scheme indicates variations in the 3T3-L1 preadipocyte differentiation and cladosporol treatment protocols used in the migration assay shown in (C). (C) The 
assay was carried out as described in (A), except that the conditioned medium was used to culture HT-29 cells for 24, 48 and 72 h and the medium collected from 
3T3-L1 cells treated with MDI plus CL A and CL B was deprived of both drugs in the last two days of cell differentiation (the new samples are indicated as MDI-CL A 
and MDI-CL B). (D) Western blotting analysis of cell cycle markers and apoptotic factors in HT-29 cells treated as described in (C). Total protein extracts from HT-29 
cells were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to nylon membranes. Subsequently, antibodies were used to 
detect the expression of β-catenin, cyclin D1, p21 and caspase 3. To control the samples loaded derived from untreated and cladosporol A- and cladosporol B-treated 
HT-29 cells and normalize the results, an anti-β-actin antibody was used. The bar graphs represent the mean ± SD of protein/β-actin of at least 2 independent 
experiments. 
Fig. 7. (continued). 
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proteins, including PPARγ and c/EBPα. In addition, cladosporol A and 
cladosporol B inversely regulated the synthesis and secretion of leptin 
and adiponectin; this action influences the proliferation and migration 
of HT-29 culture cells. Indeed, cladosporols display the ability to break 
the crosstalk between mature adipocytes and CRC cells. This action of-
fers a promising approach to inhibit concomitantly adipogenesis and the 
progression of CRC cells and tumors. 
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